List view / Grid view
Radiopharmaceuticals represent a rapidly advancing field in oncology, using radioactive compounds to both detect and treat cancer at the molecular level. This article explores how targeted radiation is improving patient outcomes while reducing systemic toxicity.
Scientists in Japan have developed a new radioactive drug that emits alpha particles, showing promise for targeting metastatic melanoma - an aggressive skin cancer resistant to many conventional treatments.
DTR speaks with Dr Patrick van Berkel at ADC Therapeutics to discuss how the company is transforming exatecan delivery to achieve better health outcomes.
The humanised antibody, Hv1Lt1, showed promising results in pancreatic cancer mouse models.
In this episode, we explore how mRNA technology could revolutionise cancer therapeutics.
Targeted alpha therapy shows promising preclinical results, increasing survival rate by 36.4 percent in recurrent tumours.
Researchers have developed a prediction model to ascertain breast cancer survivors’ risk of persistent taxane-induced peripheral neuropathy.
Researchers have discovered that pancreatic cancer’s resistance to chemotherapy is related to the physical stiffness of the extracellular matrix.
Researchers have developed a 3D approach to improve the characterisation of pancreatic intraepithelial neoplasias.
The combination therapy worked faster and was lessened the number of leukaemia cells compared to asparaginase or venetoclax alone.
Dr Richard Cote and Dr Ramaswamy Govindan of the Washington University School of Medicine elucidate how AI, particularly deep learning networks, could identify histopathologic features in non-small cell lung cancer, and impact the treatment approach for early-stage patients.
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies.
The findings from DNA and RNA sequencing in primary and metastatic UTUC tumours could lead to strategies to improve patient outcomes.
A new study proves that organoid drug testing is highly accurate at predicting effective treatments and finds a novel therapeutic option.
Researchers suggest that DA histology slowly emerges by accumulating burdens of DNA damage and copy number aberrations.
